Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sagimet Biosciences Inc.

3.74
+0.23006.55%
Volume:281.00K
Turnover:1.04M
Market Cap:120.41M
PE:-2.90
High:3.80
Open:3.55
Low:3.50
Close:3.51
Loading ...

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

GlobeNewswire
·
18 Nov 2024

Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Nov 2024

Promising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation

TIPRANKS
·
16 Nov 2024

Sagimet Biosciences Advances MASH Treatment with Denifanstat

TIPRANKS
·
15 Nov 2024

Sagimet Biosciences, Inc.: Strategic Advancements and Financial Robustness Drive Buy Rating

TIPRANKS
·
15 Nov 2024

Sagimet Biosciences Q3 EPS $(0.45) Misses $(0.42) Estimate

Benzinga
·
14 Nov 2024

Sagimet Biosciences Inc: Anticipated Cash Runway Through 2025

THOMSON REUTERS
·
14 Nov 2024

Press Release: Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Dow Jones
·
14 Nov 2024

Sagimet Biosciences Inc : UBS Initiates Coverage With Buy Rating and Target Price $12

THOMSON REUTERS
·
12 Nov 2024

UBS Initiates Sagimet Biosciences at Buy With $12 Price Target

MT Newswires Live
·
12 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Nov 2024

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
08 Nov 2024

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

GlobeNewswire
·
07 Nov 2024

Sagimet Biosciences Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Oct 2024

Sagimet Biosciences’ Denifanstat: Promising Phase 3 Prospects and Strong Buy Recommendation

TIPRANKS
·
31 Oct 2024

BRIEF-Sagimet Biosciences Announces Successful Completion Of End-Of-Phase 2 Interactions With FDA On The Development Of Denifanstat For Mash Phase 3 Program Initiation Expected By End Of 2024

Reuters
·
29 Oct 2024